S&P Futures
5,997.75 -6.00 (-0.10%) Dow Futures
43,909.00 -1.00 (-0.00%) Nasdaq Futures
21,166.50 -58.25 (-0.27%) Russell 2000 Futures
2,395.20 -0.50 (-0.02%) Crude Oil
71.51 -0.85 (-1.17%) Gold
2,697.80 -8.00 (-0.30%)
OSE Immunotherapeutics SA (OSE.PA)
| Previous Close | 10.06 |
| Open | 10.06 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 9.86 - 10.20 |
| 52 Week Range | 3.12 - 11.58 |
| Volume | |
| Avg. Volume | 223,145 |
| Market Cap | 217.665M |
| Beta (5Y Monthly) | 0.81 |
| PE Ratio (TTM) | 5.77 |
| EPS (TTM) | 1.73 |
| Earnings Date | Sep 26, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 14.20 |
GlobeNewswireOSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis
OSE Immunotherapeutics Announces Statistically Significant and Clinically Meaningful Results from the Phase 2 Study of Anti-IL7R mAb Lusvertikimab for the Treatment of Ulcerative Colitis Lusvertikimab met the primary endpoint (modified Mayo Score improvement) at each dose tested during the 10 week-induction period of treatment in the randomized double-blind CoTikiS Phase 2 study. Highly favorable positive results on the key secondary endpoints demonstrating significantly high rate of clinical an
- GlobeNewswire
OSE Immunotherapeutics Presents New “Cis-Demasking” Bispecific Technology for the Design of Cytokine Drugs with Improved Therapeutic Index
NANTES, France, October 17, 6:00pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced it will be presenting its novel OSE-CYTOMASK Cis-Demasking1 cytokine technology in oral presentations selected for international conferences: The Festival of Biologics in Basel, Switzerland (October 17, 2024)The 16th Annual Protein & Antibody Engineering Summit (PEGS) Europe Summit in Barcelona, Spain (November 7, 2024)The Antibody Therapeutics Xchange in Brussels (November 18, 20
